{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:12:01Z","timestamp":1782947521722,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.mayocp.2026.03.018","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:57:10Z","timestamp":1775098630000},"page":"1091-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redefining Initial Rheumatoid Arthritis Treatment: Tofacitinib Outperforms Methotrexate in Disease Control\u2014An Open-Label Randomized Controlled Trial"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9547-887X","authenticated-orcid":false,"given":"Juan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-9141","authenticated-orcid":false,"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2026.03.018_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41927-024-00412-8","article-title":"Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study","volume":"8","author":"Hidayat","year":"2024","journal-title":"BMC Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.018_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.37723","article-title":"Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis","volume":"65","author":"Wasko","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9313","key":"10.1016\/j.mayocp.2026.03.018_bib3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.018_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2026.03.018_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2021-220112","article-title":"Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020","volume":"80","author":"Xie","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.018_bib6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.018_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mayocp.2026.03.018_bib8","article-title":"NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.018_bib9","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2665-9913(22)00186-2","article-title":"Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial","volume":"4","author":"Lend","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"25","key":"10.1016\/j.mayocp.2026.03.018_bib10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.018_bib11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kead515","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?","volume":"63","author":"Lauper","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.018_bib12","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1007\/s12325-023-02607-w","article-title":"Real-world data of adherence and drug survival of biologics in treatment-na\u00efve and treatment-experienced adult patients with rheumatoid arthritis","volume":"40","author":"Rosenberg","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.018_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mayocp.2023.08.029","article-title":"Real-world clinical equivalence of generic and branded tofacitinib: a prospective longitudinal cohort study in patients with rheumatoid arthritis","volume":"99","author":"Zhao","year":"2024","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.018_bib14","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s10067-022-06205-z","article-title":"Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India","volume":"41","author":"Phatak","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.018_bib15","doi-asserted-by":"crossref","DOI":"10.1213\/ANE.0000000000006498","article-title":"Safety profile of Diprospan for local infiltration in diabetic patients","volume":"136","author":"Rudingwa","year":"2023","journal-title":"Anesth Analg"},{"issue":"12","key":"10.1016\/j.mayocp.2026.03.018_bib16","first-page":"2485","article-title":"Musculoskeletal ultrasound including definitions for ultrasonographic pathology","volume":"32","author":"Wakefield","year":"2005","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.018_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.10877","article-title":"Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis","volume":"48","author":"Szkudlarek","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.018_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000262","article-title":"Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis","volume":"2","author":"Fleischmann","year":"2016","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.018_bib19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"Conaghan","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.018_bib20","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/1756-185X.14801","article-title":"Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: an open-label randomized controlled trial","volume":"26","author":"Khan","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.018_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.018_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.018_bib23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s10067-024-07084-2","article-title":"Effect of disease duration on the use of tofacitinib: a real-world study in elderly patients with rheumatoid arthritis","volume":"43","author":"Wang","year":"2024","journal-title":"Clin Rheumatol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626184456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626184456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:24:11Z","timestamp":1782905051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626184456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0025619626184456"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.03.018","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining Initial Rheumatoid Arthritis Treatment: Tofacitinib Outperforms Methotrexate in Disease Control\u2014An Open-Label Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}